50% or greater reduction in seizure frequency Number of seizures · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher reduction in seizure frequency of ≥ 50%: primary analysisNumber of… compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawalNumber of participants withdrawn for any reason · people with drug‐resistant focal epilepsy
Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: ataxia Number of participants experiencing ataxia · people with drug‐resistant focal epilepsy
Gabapentin may leads to higher adverse effects: ataxiaNumber of participants experiencing ataxia compared with placebo (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
Gabapentin may leads to higher adverse effects: fatigueNumber of participants experiencing fatigue compared with placebo (low certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Gabapentin probably leads to lower adverse effects: nauseaNumber of participants experiencing nausea compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
Gabapentin probably leads to lower adverse effects: headacheNumber of participants experiencing headache compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with postherpetic neuralgia
1 finding from 1 review
Withdrawals due to adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Death · adults with neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
IMMPACT definition ‐ any substantial pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with postherpetic neuralgia
1 finding from 1 review
IMMPACT definition ‐ any at least moderate pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · people with diabetic peripheral neuropathy
1 finding from 1 review
'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved) · people with diabetic peripheral neuropathy
1 finding from 1 review
Patient Global Impression of Change much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with neuropathic pain
1 finding from 1 review